| Host: |
HEK293 cells |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human LILRA3/CD85e-C-His & Avi protein was developed from hek293 cells and has a target region of C-His & Avi. For use in research applications. |
| Conjugation: |
Biotin |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Endotoxin: |
Less than 1EU per Mu g by the LAL method. |
| Gene Symbol: |
LILRA3 |
| Gene ID: |
11026 |
| Uniprot ID: |
LIRA3_HUMAN |
| Immunogen Region: |
Gly24-Glu439 |
| Immunogen: |
Recombinant Biotinylated Human LILRA3/CD85e Protein is expressed from Expi293 with His tag and Avi Tag at the C-terminal.；It contains Gly24-Glu439. |
| Post Translational Modifications | N-glycosylation is required for ligand binding. |
| Function | Acts as soluble receptor for class I MHC antigens. Binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1 or LILRB2. Binds with high affinity to the surface of monocytes, leading to abolish LPS-induced TNF-alpha production by monocytes. |
| Protein Name | Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 3Cd85 Antigen-Like Family Member EImmunoglobulin-Like Transcript 6Ilt-6Leukocyte Immunoglobulin-Like Receptor 4Lir-4Monocyte Inhibitory Receptor Hm43/Hm31Cd Antigen Cd85e |
| Database Links | Reactome: R-HSA-198933Reactome: R-HSA-6798695 |
| Cellular Localisation | Secreted |
| Alternative Protein Names | Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 3 proteinCd85 Antigen-Like Family Member E proteinImmunoglobulin-Like Transcript 6 proteinIlt-6 proteinLeukocyte Immunoglobulin-Like Receptor 4 proteinLir-4 proteinMonocyte Inhibitory Receptor Hm43/Hm31 proteinCd Antigen Cd85e proteinLILRA3 proteinILT6 proteinLIR4 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
